StudyFinder

RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER

Status: Recruiting

I'm interested

This study is NOT accepting healthy volunteers

Conditions:

Anatomic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8

Contact(s): Ava Athmann - ava.athmann@parknicollet.com

Principal Investigator: Nicole Hartung

IRB Number: 0123456789

System ID: 0123456789

See this study on ClinicalTrials.gov

Back

RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER

Email this study information to me

Contact the study team